

Please type a plus (+) inside this box → ☐

11-29-00

A

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JC867 U.S. PTO

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 6261-227

Total Pages

First Named Inventor or Application Identifier

Robert S. LANGER

Express Mail Label No.

EL 501 635 613 US

11/28/00
09/22/00
U.S. PTO

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. ☒ Specification [Total Pages 32]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description of the Invention (including drawings, if filed)
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 USC 113) [Total Sheets 5]
- ☒ Oath or Declaration [Total Sheets 5]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ DELETION OF INVENTORS(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
- ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☒ Other: Copy Revocation and Powers of Attorney executed by University Technology Corporation, The General Hospital Corporation, and Massachusetts Institute of Technology

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:
☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 08/862,740 filed May 23, 1997.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

20583

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME					
ADDRESS					
CITY	STATE	ZIP CODE			
COUNTRY	TELEPHONE	FAX			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Express Mail No.: EL 501 635 613 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

JC784 U.S. PTO
09/724382
 11/28/00

Prior application: Examiner Edward J. WebmanArt Unit 1617

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of pending prior application no. 08/862,740 filed on May 23, 1997.

of Robert S. LANGER; Jennifer ELISSEFF; Kristi ANSETH; and Derek SIMS
 (inventor(s) currently of record in prior application)

for SEMI-INTERPENETRATING OR INTERPENETRATING POLYMER NETWORKS FOR DRUG DELIVERY AND TISSUE ENGINEERING
 (title of invention)

1. ☒ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	7	-20	0	\$18.00 each	\$ 0.00
Independent	1	-3	0	\$80.00 each	\$ 0.00
Basic Fee					\$ 710.00
Multiple Dependency Fee If Applicable (\$270.00)					\$ 0.00
Total					\$ 710.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- \$ 0.00
Total Filing Fee					\$ 710.00

2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
3. ☒ Amend the specification by inserting before the first line the following sentence: This is a continuation of application no. 08/862,740, filed May 23, 1997.

- 4a. ☐ Transfer the drawings from the prior application to this application and abandon the prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
- 4b. ☐ New formal drawings are enclosed.
- 4c. ☒ Informal drawings are enclosed.
- 5a. ☐ Priority of application no. filed on in is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. , filed .
6. ☒ The prior application is assigned of record to University Technology Corporation at Reel 9192, Frame 0949; The General Hospital Corporation at Reel 9192, Frame 0879; and Massachusetts Institute of Technology at Reel 9196, Frame 0120.
- 7a. ☐ The Power of Attorney appears in the original papers in the prior application no. , filed .
- 7b. ☐ Since the Power of Attorney does not appear in the original papers, a copy of the Power in prior application no. , filed is enclosed.
8. ☐ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no., filed on be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. is enclosed.
9. ☐ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. is the same as the content of the computer readable form submitted in application no. .
10. ☒ Additional enclosures or instructions. Copy of Revocation and Power of Attorney from application No. 08/862,740, filed on May 23, 1997.

Respectfully submitted,

Laura A. Coruzzi by
Maria E Pasquale Reg No. 38,265
30,742

Date November 28, 2000

Laura A. Coruzzi (Reg. No.)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090

SEMI-INTERPENETRATING OR INTERPENETRATING POLYMER NETWORKS FOR DRUG DELIVERY AND TISSUE ENGINEERING

Background of the Invention

5 The United States government has certain rights in this invention by
virtue of grant AR08387 NIH Fellowship 23464 to Robert S. Langer.

This application claims priority to U.S. Serial No. filed April 11,
1997, Express Mail Label No. EM290166797US.

10 The present invention is generally in the area of using polymeric
semi-interpenetrating and interpenetrating polymer network compositions and
photocrosslinkable polymeric hydrogels in medical treatments, especially joint
resurfacing and plastic surgery and delivery of drugs.

Congenital Defects

15 Many congenital defects, especially in the urogenital areas, require
surgical correction. Examples include treatment of reflux and urinary
incontinence. WO 94/25080 by Massachusetts Institute of Technology
describes the use of injectable polysaccharide-cell compositions for delivering
isolated cells by injection, which then form new tissue that is effective as a
bulking agent. The polymers that are described crosslink ionically, as a
function of ionic strength, temperature, pH, or combinations thereof. WO
20 96/40304 by Reprogenesis describes similar applications of polymeric
hydrogels formed by covalent crosslinking, for example, by
photopolymerization of the injected polymer-cell suspension using a catheter
or during surgery.

Craniofacial contour deformities

25 Craniofacial contour deformities, whether traumatic, congenital, or
aesthetic, currently require invasive surgical techniques for correction.
Furthermore, deformities requiring augmentation often necessitate the use of
alloplastic prostheses which suffer from problems of infection and extrusion.
Correction of these defects and irregularities remain a difficult and
30 controversial problem. Sims, et al., reported in Plastic Reconstructive

Surgery 98:845 (1996), the formation of new cartilage from injected polyethylene oxide-cell suspensions, and suggested that this technology would be useful in plastic surgery.

Replacement or Repair of Cartilaginous Surfaces

5 The aging population, especially of those active in sports and in jobs creating stress on joints, have little recourse at this time for repair or replacement of cartilage. Arthroscopic surgery can be used to remove torn cartilage but highly invasive and painful surgery is required for repair or replacement of a joint having little cartilage left. In most cases a prosthetic
10 device must be used to replace the entire joint, following destruction of the smooth cartilaginous surface which normally allows for free movement of the abutting joint surfaces. As described in U.S. Patent No. 5,514,378 to Vacanti, et al., it has been proposed to create new joint surfaces using a synthetic polymeric mesh seeded with chondrocytes, which forms new
15 cartilage as the polymer degrades. Although this is promising, the seeded mesh must still be implanted surgically.

 There is a need for improved injectable polymer-cell compositions which are biocompatible and biodegradable for delivering isolated cells by injection. There is a further need for less invasive means of covalently
20 crosslinking polymer-cell suspensions following injection.

 Accordingly, it is an object of the present invention to provide methods and compositions for injection of cells to form cellular tissues and cartilaginous structures, based on interpenetrating networks of synthetic
25 polymers.

 It is a further object of the invention to provide improved compositions to form cellular tissues and cartilaginous structures including non-cellular material which will degrade and be removed to leave tissue or cartilage that is histologically and chemically the same as naturally produced tissue or cartilage.

It is another object of the present invention to provide compositions for and a method for covalent crosslinking a polymer-cell suspension for formation of new tissue following injection.

Summary of the Invention

5 Compositions for tissue engineering and drug delivery have been developed based on solutions of two or more polymers which form semi-interpenetrating or interpenetrating polymer networks upon exposure to active species following injection at a site in a patient in need thereof. The polymers crosslink to themselves but not to each other; semi-interpenetrating
10 networks are formed when only one of the polymers crosslink. The resulting viscous solutions retain the biologically active molecules or cells at the site of injection until release or tissue formation, respectfully, occurs.

As a result of studies conducted with polymer-cell suspensions forming interpenetrating polymer networks, it has been determined that
15 polymer solutions can be formulated wherein the active species is provided by exposure of the polymer solution to an exogenous source of active species, typically electromagnetic radiation, preferably light. Studies demonstrate that light will penetrate through skin, body fluids (such as synovial fluid) and membranes and polymerize the polymer solutions. The
20 polymer solutions can be crosslinked ionically or covalently, to form a hydrogel, semi-interpenetrating polymer network or an interpenetrating polymer network.

Brief Description of the Drawings

Figure 1 graphically depicts the rate of polymerization, **A**, and
25 percent conversion of a polymerizable solution to a polymer matrix, **B**, over time with a photoactive initiator and ultraviolet light.

Figure 2 graphically sets for the calculated rate (time in minutes) of photopolymerization of a polymerizable solution under the subcutaneous, **A**, subcutaneous and fat, **B**, and subcutaneous and fat and muscle, **C**, layers of rat skin based upon the penetration of light through these layers.

5 Figure 3 graphically depicts the effect of succinic acid (SAD) concentration on the equilibrium swelling volume of a polymer, for polymers of molecular weight 1000 and 3400.

 Figure 4 graphically depicts the effect of succinic acid concentration (17%, 43%, 51%, and 0% SAD) on release of serum albumin (percent) from
10 a polymer over time (days).

 Figure 5 graphically depicts the effect of succinic acid concentration (19% and 21% SAD) on the release of rhodamine from a polymer (percent over time in days).

Detailed Description of the Invention

15 Techniques of tissue engineering employing biocompatible polymer scaffolds hold promise as a means of creating alternatives to prosthetic materials currently used in plastic surgery and joint repair or replacement, as well as formation of organ equivalents to replaced diseased, defective, or injured tissues.

20 Interpenetrating networks ("IPN") are defined as networks where two components are crosslinked, but not to each other. As described herein, in one embodiment, semi-interpenetrating networks of synthetic and/or natural polymers are used as the polymeric support for cells to be injected. Semi-interpenetrating networks are defined as solutions that include two
25 independent components, where one component is a crosslinked polymer and the other component is a non-crosslinked polymer. The crosslinked polymer preferably constitutes between about 10 and 90 % by weight of the semi-interpenetrating network composition.

The semi-interpenetrating polymer networks are preferably prepared from hydrophilic polymers. In one embodiment, the polymer networks include a hydrophilic polymer with groups crosslinkable with active species and/or ionically crosslinkable groups, and a hydrophilic polymer with no active species or ionically crosslinkable groups.

In a second embodiment, cells are suspended in a polymer solution which can be crosslinked by active species generation, preferably by photoactivation. The suspension is injected at the site where new tissue is to be formed. Light is then applied externally to the skin to crosslink the injected polymer. This method is based on the discovery that combinations of polymers and photoinitiators (in a concentration not toxic to the cells, less than 0.1% by weight, more preferably between 0.05 and 0.01% by weight percent initiator) will crosslink upon exposure to light equivalent to between one and 3 mWatts/cm² applied to the skin of nude mice. Although discussed herein principally with regard to administration of a light source external to the skin, this should be interpreted as equally applicable to light applied through tissues, for example, from a catheter in a blood vessel adjacent to a tissue where the polymer-cell suspension has been injected, or in the synovial space adjacent to a cartilaginous surface to be repaired or replaced with injected polymer-cell suspension.

Polymer Compositions

The polymer compositions can consist solely of covalently crosslinkable polymers, as described in WO96/40304, in combination with an effective but non-toxic amount of photoinitiator to allow crosslinking using radiation provided by an external source, or blends of covalently and ionically crosslinkable or hydrophilic polymers which when exposed to radiation form semi-interpenetrating networks having cells suspended therein.

Ionically crosslinkable and Hydrophilic Polymers

As used herein, "hydrophilic polymers" are defined as polymers with a solubility of at least ten grams/liter of an aqueous solution at a temperature

of between about 0 and 50°C. Aqueous solutions can include small amounts of water-soluble organic solvents, such as dimethylsulfoxide, dimethylformamide, alcohols, acetone, and/or glymes.

Suitable hydrophilic polymers include synthetic polymers such as poly(ethylene glycol), poly(ethylene oxide), partially or fully hydrolyzed poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers (poloxamers and meroxapols), poloxamines, carboxymethyl cellulose, and hydroxyalkylated celluloses such as hydroxyethyl cellulose and methylhydroxypropyl cellulose, and natural polymers such as polypeptides, polysaccharides or carbohydrates such as Ficoll® polysucrose, hyaluronic acid, dextran, heparan sulfate, chondroitin sulfate, heparin, or alginate, and proteins such as gelatin, collagen, albumin, or ovalbumin or copolymers or blends thereof. As used herein, "celluloses" includes cellulose and derivatives of the types described above; "dextran" includes dextran and similar derivatives thereof.

Examples of materials which can be used to form a hydrogel include modified alginates. Alginate is a carbohydrate polymer isolated from seaweed, which can be crosslinked to form a hydrogel by exposure to a divalent cation such as calcium, as described, for example in WO 94/25080, the disclosure of which is incorporated herein by reference. Alginate is ionically crosslinked in the presence of divalent cations, in water, at room temperature, to form a hydrogel matrix. Modified alginate derivatives may be synthesized which have an improved ability to form hydrogels. The use of alginate as the starting material is advantageous because it is available from more than one source, and is available in good purity and characterization. As used herein, the term "modified alginates" refers to chemically modified alginates with modified hydrogel properties. Naturally occurring alginate may be chemically modified to produce alginate polymer derivatives that degrade more quickly. For example, alginate may be

chemically cleaved to produce smaller blocks of gellable oligosaccharide blocks and a linear copolymer may be formed with another preselected moiety, e.g. lactic acid or ϵ -caprolactone. The resulting polymer includes alginate blocks which permit ionically catalyzed gelling, and oligoester blocks which produce more rapid degradation depending on the synthetic design. Alternatively, alginate polymers may be used wherein the ratio of mannuronic acid to guluronic acid does not produce a firm gel, which are derivatized with hydrophobic, water-labile chains, e.g., oligomers of ϵ -caprolactone. The hydrophobic interactions induce gelation, until they degrade in the body.

Additionally, polysaccharides which gel by exposure to monovalent cations, including bacterial polysaccharides, such as gellan gum, and plant polysaccharides, such as carrageenans, may be crosslinked to form a hydrogel using methods analogous to those available for the crosslinking of alginates described above. Polysaccharides which gel in the presence of monovalent cations form hydrogels upon exposure, for example, to a solution comprising physiological levels of sodium. Hydrogel precursor solutions also may be osmotically adjusted with a nonion, such as mannitol, and then injected to form a gel.

Polysaccharides that are very viscous liquids or are thixotropic, and form a gel over time by the slow evolution of structure, are also useful. For example, hyaluronic acid, which forms an injectable gel with a consistency like a hair gel, may be utilized. Modified hyaluronic acid derivatives are particularly useful. As used herein, the term "hyaluronic acids" refers to natural and chemically modified hyaluronic acids. Modified hyaluronic acids may be designed and synthesized with preselected chemical modifications to adjust the rate and degree of crosslinking and biodegradation. For example, modified hyaluronic acids may be designed and synthesized which are esterified with a relatively hydrophobic group such as propionic acid or benzylic acid to render the polymer more hydrophobic and gel-forming, or

which are grafted with amines to promote electrostatic self-assembly. Modified hyaluronic acids thus may be synthesized which are injectable, in that they flow under stress, but maintain a gel-like structure when not under stress. Hyaluronic acid and hyaluronic derivatives are available from
5 Genzyme, Cambridge, MA and Fidia, Italy.

Other polymeric hydrogel precursors include polyethylene oxide-polypropylene glycol block copolymers such as Pluronics™ or Tetronics™, which are crosslinked by hydrogen bonding and/or by a temperature change, as described in Steinleitner *et al.*, *Obstetrics & Gynecology*, 77:48-52 (1991);
10 and Steinleitner *et al.*, *Fertility and Sterility*, 57:305-308 (1992). Other materials which may be utilized include proteins such as fibrin, collagen and gelatin. Polymer mixtures also may be utilized. For example, a mixture of polyethylene oxide and polyacrylic acid which gels by hydrogen bonding upon mixing may be utilized. In one embodiment, a mixture of a 5% w/w
15 solution of polyacrylic acid with a 5% w/w polyethylene oxide (polyethylene glycol, polyoxyethylene) 100,000 can be combined to form a gel over the course of time, *e.g.*, as quickly as within a few seconds.

Water soluble polymers with charged side groups may be crosslinked by reacting the polymer with an aqueous solution containing ions of the
20 opposite charge, either cations if the polymer has acidic side groups or anions if the polymer has basic side groups. Examples of cations for cross-linking of the polymers with acidic side groups to form a hydrogel are monovalent cations such as sodium, divalent cations such as calcium, and multivalent cations such as copper, calcium, aluminum, magnesium,
25 strontium, barium, and tin, and di-, tri- or tetra-functional organic cations such as alkylammonium salts. Aqueous solutions of the salts of these cations are added to the polymers to form soft, highly swollen hydrogels and membranes. The higher the concentration of cation, or the higher the valence, the greater the degree of cross-linking of the polymer. Additionally,
30 the polymers may be crosslinked enzymatically, *e.g.*, fibrin with thrombin.

Suitable ionically crosslinkable groups include phenols, amines, imines, amides, carboxylic acids, sulfonic acids and phosphate groups. Aliphatic hydroxy groups are not considered to be reactive groups for the chemistry disclosed herein. Negatively charged groups, such as carboxylate, sulfonate and phosphate ions, can be crosslinked with cations such as calcium ions. The crosslinking of alginate with calcium ions is an example of this type of ionic crosslinking. Positively charged groups, such as ammonium ions, can be crosslinked with negatively charged ions such as carboxylate, sulfonate and phosphate ions. Preferably, the negatively charged ions contain more than one carboxylate, sulfonate or phosphate group.

In the embodiment wherein modified alginates and other anionic polymers that can form hydrogels which are malleable are used to encapsulate cells, the hydrogel is produced by cross-linking the polymer with the appropriate cation, and the strength of the hydrogel bonding increases with either increasing concentrations of cations or of polymer. Concentrations from as low as 0.001 M have been shown to cross-link alginate. Higher concentrations are limited by the toxicity of the salt.

The preferred anions for cross-linking of the polymers to form a hydrogel are monovalent, divalent or trivalent anions such as low molecular weight dicarboxylic acids, for example, terephthalic acid, sulfate ions and carbonate ions. Aqueous solutions of the salts of these anions are added to the polymers to form soft, highly swollen hydrogels and membranes, as described with respect to cations.

A variety of polycations can be used to complex and thereby stabilize the polymer hydrogel into a semi-permeable surface membrane. Examples of materials that can be used include polymers having basic reactive groups such as amine or imine groups, having a preferred molecular weight between 3,000 and 100,000, such as polyethylenimine and polylysine. These are commercially available. One polycation is poly(L-lysine); examples of synthetic polyamines are: polyethyleneimine, poly(vinylamine), and poly(allyl

amine). There are also natural polycations such as the polysaccharide, chitosan.

Polyanions that can be used to form a semi-permeable membrane by reaction with basic surface groups on the polymer hydrogel include polymers and copolymers of acrylic acid, methacrylic acid, and other derivatives of acrylic acid, polymers with pendant SO₃H groups such as sulfonated polystyrene, and polystyrene with carboxylic acid groups.

These polymers can be modified to contain active species polymerizable groups and/or ionically crosslinkable groups. Methods for modifying hydrophilic polymers to include these groups are well known to those of skill in the art.

The polymers may be intrinsically biodegradable, but are preferably of low biodegradability (for predictability of dissolution) but of sufficiently low molecular weight to allow excretion. The maximum molecular weight to allow excretion in human beings (or other species in which use is intended) will vary with polymer type, but will often be about 20,000 daltons or below. Usable, but less preferable for general use because of intrinsic biodegradability, are water-soluble natural polymers and synthetic equivalents or derivatives, including polypeptides, polynucleotides, and degradable polysaccharides.

The polymers can be a single block with a molecular weight of at least 600, preferably 2000 or more, and more preferably at least 3000. Alternatively, the polymers can include can be two or more water-soluble blocks which are joined by other groups. Such joining groups can include biodegradable linkages, polymerizable linkages, or both. For example, an unsaturated dicarboxylic acid, such as maleic, fumaric, or aconitic acid, can be esterified with hydrophilic polymers containing hydroxy groups, such as polyethylene glycols, or amidated with hydrophilic polymers containing amine groups, such as poloxamines.

Covalently Crosslinkable Polymer Solutions

Covalently crosslinkable hydrogel precursors also are useful. For example, a water soluble polyamine, such as chitosan, can be cross-linked with a water soluble diisothiocyanate, such as polyethylene glycol diisothiocyanate. The isothiocyanates will react with the amines to form a chemically crosslinked gel. Aldehyde reactions with amines, e.g., with polyethylene glycol dialdehyde also may be utilized. A hydroxylated water soluble polymer also may be utilized.

Alternatively, polymers may be utilized which include substituents which are crosslinked by a radical reaction upon contact with a radical initiator. For example, polymers including ethylenically unsaturated groups which can be photochemically crosslinked may be utilized, as disclosed in WO 93/17669, the disclosure of which is incorporated herein by reference. In this embodiment, water soluble macromers that include at least one water soluble region, a biodegradable region, and at least two free radical-polymerizable regions, are provided. The macromers are polymerized by exposure of the polymerizable regions to free radicals generated, for example, by photosensitive chemicals and or light. Examples of these macromers are PEG-oligolactyl-acrylates, wherein the acrylate groups are polymerized using radical initiating systems, such as an eosin dye, or by brief exposure to ultraviolet or visible light. Additionally, water soluble polymers which include cinnamoyl groups which may be photochemically crosslinked may be utilized, as disclosed in Matsuda *et al.*, *ASAID Trans.*, 38:154-157 (1992).

The term "active species polymerizable group" is defined as a reactive functional group that has the capacity to form additional covalent bonds resulting in polymer interlinking upon exposure to active species. Active species include free radicals, cations, and anions. Suitable free radical polymerizable groups include ethylenically unsaturated groups (i.e., vinyl groups) such as vinyl ethers, allyl groups, unsaturated monocarboxylic acids,

5

10

15

25

30

percentages are preferable, and excellent gels can be obtained in polymer mixtures in which most or all of the molecules have two or more reactive double bonds. Poloxamines, an example of a hydrophilic polymer, have four arms and thus may readily be modified to include four polymerizable groups.

5 Photoinitiators

Polymerization is preferably initiated using photoinitiators.

Photoinitiators that generate a active species on exposure to UV light are well known to those of skill in the art. Active species can also be formed in a relatively mild manner from photon absorption of certain dyes and chemical compounds.

10 These groups can be polymerized using photoinitiators that generate active species upon exposure to UV light, or, preferably, using long-wavelength ultraviolet light (LWUV) or visible light. LWUV and visible light are preferred because they cause less damage to tissue and other biological materials than UV light. Useful photoinitiators are those which can be used to initiate polymerization of the macromers without cytotoxicity and within a short time frame, minutes at most and most preferably seconds.

15 Exposure of dyes and cocatalysts such as amines to visible or LWUV light can generate active species. Light absorption by the dye causes the dye to assume a triplet state, and the triplet state subsequently reacts with the amine to form a active species which initiates polymerization.

20 Polymerization can be initiated by irradiation with light at a wavelength of between about 200-700 nm, most preferably in the long wavelength ultraviolet range or visible range, 320 nm or higher, and most preferably between about 365 and 514 nm.

25 Numerous dyes can be used for photopolymerization. Suitable dyes are well known to those of skill in the art. Preferred dyes include erythrosin, phloxime, rose bengal, thionine, camphorquinone, ethyl eosin, eosin, methylene blue, riboflavin, 2,2-dimethyl-2-phenylacetophenone, 2-methoxy-2-phenylacetophenone, 2,2-dimethoxy-2-phenyl acetophenone, other

30

acetophenone derivatives, and camphorquinone. Suitable cocatalysts include amines such as N-methyl diethanolamine, N,N-dimethyl benzylamine, triethanol amine, triethylamine, dibenzyl amine, N-benzylethanolamine, N-isopropyl benzylamine. Triethanolamine is a preferred cocatalyst.

5 Photopolymerization of these polymer solutions is based on the discovery that combinations of polymers and photoinitiators (in a concentration not toxic to the cells, less than 0.1% by weight, more preferably between 0.05 and 0.01% by weight percent initiator) will crosslink upon exposure to light equivalent to between one and 3 mWatts/cm² applied
10 to the skin of nude mice.

Figure 1 demonstrates the extent of conversion of a polymer solution over time as compared to the rate of polymerization.

Source of Cells

Cells can be obtained directed from a donor, from cell culture of cells
15 from a donor, or from established cell culture lines. In the preferred embodiment, cells of the same species and preferably immunological profile are obtained by biopsy, either from the patient or a close relative, which are then grown to confluence in culture using standard conditions and used as needed. If cells that are likely to elicit an immune reaction are used, such as
20 human muscle cells from immunologically distinct individual, then the recipient can be immunosuppressed as needed, for example, using a schedule of steroids and other immunosuppressant drugs such as cyclosporine. However, in the most preferred embodiment, the cells are autologous.

In the preferred embodiments, cells are obtained directly from a
25 donor, washed and implanted directly in combination with the polymeric material. The cells are cultured using techniques known to those skilled in the art of tissue culture. Cells obtained by biopsy are harvested and cultured, passaging as necessary to remove contaminating cells. Isolation of chondrocytes and muscle cells is demonstrated in WO 94/25080, the
30 disclosure of which is incorporated herein.

Cell attachment and viability can be assessed using scanning electron microscopy, histology, and quantitative assessment with radioisotopes. The function of the implanted cells can be determined using a combination of the above-techniques and functional assays. For example, in the case of

5 hepatocytes, *in vivo* liver function studies can be performed by placing a cannula into the recipient's common bile duct. Bile can then be collected in increments. Bile pigments can be analyzed by high pressure liquid chromatography looking for underivatized tetrapyrroles or by thin layer chromatography after being converted to azodipyrroles by reaction with

10 diazotized azodipyrroles ethylantranilate either with or without treatment with P-glucuronidase. Diconjugated and monoconjugated bilirubin can also be determined by thin layer chromatography after alkalinemethanolysis of conjugated bile pigments. In general, as the number of functioning transplanted hepatocytes increases, the levels of conjugated bilirubin will

15 increase. Simple liver function tests can also be done on blood samples, such as albumin production.

Analogous organ function studies can be conducted using techniques known to those skilled in the art, as required to determine the extent of cell function after implantation. For example, islet cells of the pancreas may be

20 delivered in a similar fashion to that specifically used to implant hepatocytes, to achieve glucose regulation by appropriate secretion of insulin to cure diabetes. Other endocrine tissues can also be implanted. Studies using labelled glucose as well as studies using protein assays can be performed to quantitate cell mass on the polymer scaffolds. These studies of cell mass can

25 then be correlated with cell functional studies to determine what the appropriate cell mass is. In the case of chondrocytes, function is defined as providing appropriate structural support for the surrounding attached tissues.

This technique can be used to provide multiple cell types, including genetically altered cells, within a three-dimensional scaffolding for the

30 efficient transfer of large number of cells and the promotion of transplant

00924382 12800

engraftment for the purpose of creating a new tissue or tissue equivalent. It can also be used for immunoprotection of cell transplants while a new tissue or tissue equivalent is growing by excluding the host immune system.

Examples of cells which can be implanted as described herein include chondrocytes and other cells that form cartilage, osteoblasts and other cells that form bone, muscle cells, fibroblasts, and organ cells. As used herein, "organ cells" includes hepatocytes, islet cells, cells of intestinal origin, cells derived from the kidney, and other cells acting primarily to synthesize and secrete, or to metabolize materials.

Biologically Active Materials added to the Polymer Suspensions.

The polymer solutions can be used for drug delivery. Examples of materials to be incorporated into the polymer solutions are proteins, polysaccharides, nucleic acid molecules, and synthetic organic or inorganic molecules. These may be useful for therapeutic, prophylactic or diagnostic purposes. Drugs may include antibiotics, antivirals, chemotherapeutic agents, anti-angiogenic agents, hormones, drugs having an effect on vascular flow, anti-inflammatories, and many others routinely used.

The polymeric matrix can be combined with humoral factors to promote cell transplantation and engraftment. For example, the polymeric matrix can be combined with angiogenic factors, antibiotics, antiinflammatories, growth factors, compounds which induce differentiation, and other factors which are known to those skilled in the art of cell culture.

For example, humoral factors could be mixed in a slow-release form with the cell-polymer suspension prior to formation of implant or transplantation. Alternatively, the hydrogel could be modified to bind humoral factors or signal recognition sequences prior to combination with isolated cell suspension.

Blends of Ionically and Covalently Crosslinkable Polymers

In a preferred embodiment, the polymer solution is formed of two or more polymers, which crosslink to form a semi-interpenetrating network.

For example, the blend could include PEO, which is ionically crosslinkable, and diamethacrylated PEO, in a range of between 10 and 40% by weight covalently crosslinkable polymer in the preferred embodiment. Alternatively, blends of two covalently crosslinkable polymers can be used, selected on the basis that they form a network of crosslinked homopolymers, not to each other. Advantages of the semi-interpenetrating networks include that the diffusion of non-crosslinked polymer can provide advantages degradation properties, and enhance mechanical properties, especially for use in plastic surgery.

Cell Suspensions

Preferably the polymer is dissolved in an aqueous solution, preferably a 0.1 M potassium phosphate solution, at physiological pH, to a concentration forming a polymeric hydrogel. The isolated cells are suspended in the polymer solution to a concentration of between 1 and 50 million cells/ml, most preferably between 10 and 20 million cells/ml.

Methods of Implantation

In the preferred embodiment, the molecules to be delivered or cells are mixed with the polymer solution and injected directly into a site where it is desired to implant the molecules or cells, prior to crosslinking of the polymer to form the hydrogel matrix.

The site, or sites, where molecules or cells are to be injected is determined based on individual need, as is the requisite amount of molecules or number of cells. For cells having organ function, for example, hepatocytes or islet cells, the mixture can be injected into the mesentery, subcutaneous tissue, retroperitoneum, peritoneal space, and intramuscular space. For formation of cartilage, the cells are injected into the site where cartilage formation is desired. One could also apply an external mold to shape the injected solution. Additionally, by controlling the rate of polymerization, it is possible to mold the cell-hydrogel injected implant like

one would mold clay. Alternatively, the mixture can be injected into a mold, the hydrogel allowed to harden, then the material implanted.

The suspension can be injected via a syringe and needle directly into a specific area wherever a bulking agent is desired, i.e., a soft tissue deformity such as that seen with areas of muscle atrophy due to congenital or acquired diseases or secondary to trauma, burns, and the like. An example of this would be the injection of the suspension in the upper torso of a patient with muscular atrophy secondary to nerve damage.

The suspension can also be injected as a bulking agent for hard tissue defects, such as bone or cartilage defects, either congenital or acquired disease states, or secondary to trauma or burns. An example of this would be an injection into the area surrounding the skull where a bony deformity exists secondary to trauma. The injunction in these instances can be made directly into the needed area with the use of a needle and syringe under local or general anesthesia.

The suspension could also be injected percutaneously by direct palpation, such as by placing a needle inside the vas deferens and occluding the same with the injected bulking substance, thus rendering the patient infertile. The suspension could also be injected through a catheter or needle with fluoroscopic, sonographic, computed tomography, magnetic resonance imaging or other type of radiologic guidance. This would allow for placement or injection of this substance either by vascular access or percutaneous access to specific organs or other tissue regions in the body, wherever a bulking agent would be required.

Further, this substance could be injected through a laparoscope or thoracoscope to any intraperitoneal or extraperitoneal or thoracic organ. For example, the suspension could be injected in the region of the gastro-esophageal junction for the correcting of gastroesophageal reflux. This could be performed either with a thoracoscope injecting the substance in the esophageal portion of the gastroesophageal region, or via a laparoscope by

injecting the substance in the gastric portion of the gastroesophageal region, or by a combined approach.

The material can also be used to treat vesicoureteral reflux. In addition to its use for the endoscopic treatment of reflux, the system of injectable autologous muscle cell may also be applicable for the treatment of other medical conditions, such as urinary and rectal incontinence, dysphonia, plastic reconstruction, and wherever an injectable permanent biocompatible material is needed. Methods for using an injectable polymer for delivering isolated cells via injection are described for example in WO 94/25080.

In addition to the use of the cell-polymer suspension for the treatment of reflux and incontinence, the suspension can also be applied to reconstructive surgery, as well as its application anywhere in the human body where a biocompatible permanent injectable material is necessary. The suspension can be injected endoscopically, for example through a laryngoscope for injection into the vocal chords for the treatment of dysphonia, or through a hysteroscope for injection into the fallopian tubes as a method of rendering the patient infertile, or through a proctoscope, for injection of the substance in the perirectal sphincter area, thereby increasing the resistance in the sphincter area and rendering the patient continent of stool.

This technology can be used for other purposes. For example, custom-molded cell implants can be used to reconstruct three dimensional tissue defects, e.g., molds of human ears could be created and a chondrocyte-hydrogel replica could be fashioned and implanted to reconstruct a missing ear. Cells can also be transplanted in the form of a three-dimensional structure which could be delivered via injection.

Application of Active Species Generators

In the preferred embodiment using photopolymerizable polymers, the light is applied externally to the tissue where the polymer suspension has been injected. Biologically active molecules or cells are suspended in a

polymer solution which can be crosslinked by active species generation, preferably by photoactivation. The suspension is injected at the site where new tissue is to be formed or drug to be released. Light is then applied externally to the skin to crosslink the injected polymer. This method is based on the discovery that combinations of polymers and photoinitiators (in a concentration not toxic to the cells, less than 0.1% by weight, more preferably between 0.05 and 0.01% by weight percent initiator) will crosslink upon exposure to light equivalent to between one and 3 mWatts/cm² applied to the skin of nude mice. Although discussed herein principally with regard to administration of a light source external to the skin, this should be interpreted as equally applicable to light applied through tissues, for example, from a catheter in a blood vessel adjacent to a tissue where the polymer-cell suspension has been injected, or in the synovial space adjacent to a cartilaginous surface to be repaired or replaced with injected polymer-cell suspension.

The depth of penetration can be controlled by the wavelength of the light utilized to cause the photopolymerization. For example, visible light penetrates deeper through tissue than UV light. Penetration through tissue can range from microns to one cm, 1 cm occurring with visible light. In a preferred embodiment, radiation of 200 to 700 nm wavelength is used to create active species and polymerize the network.

A minimum of 0.01 mW/cm² intensity is needed to induce polymerization. Maximum light intensity can range from one to 1000 mW/cm² depending upon the wavelength of radiation. Higher light intensities can be exposed to tissue for example, with longer wavelength, visible light which causes less tissue/cell damage than shortwave UV light. In dental applications, blue light (470-490 nm) is used at intensities of 100 to 400 mW/cm² clinically.

The intensity of the radiation is controlled to minimize cell exposure in the case of injection of polymer-cell suspensions. In the nude mouse, the

cells were exposed to 1 to 3 mW/cm² UVA light. By knowing the thickness of the tissue and the decrease in radiation intensity as it passes through tissue, one can predict and control the light intensity to which the cells are exposed. It is desirable to have the cell-polymer suspension exposed to light of the minimum intensity needed to cause the formation of active species and polymerization.

The teachings of the cited publications are indicative of the level of skill and the general knowledge of those skilled in the art. To the extent necessary, the publications are specifically incorporated herein by reference.

Where appropriate, the following definitions are to be used.

"Electromagnetic Radiation" as used herein refers to energy waves of the electromagnetic spectrum including, but not limited to, x-ray, ultraviolet, visible, infrared, far infrared, microwave and radio-frequency.

"Visible light" as used herein refers to energy waves having a wavelength of at least approximately 4.0×10^{-5} cm.

"Ultraviolet light" as used herein refers to energy waves having a wavelength of at least approximately 1.0×10^{-5} cm but less than 7.0×10^{-5} cm.

"Ultraviolet light" as used herein refers to energy waves having a wavelength of at least approximately 1.0×10^{-5} cm but less than 4.0×10^{-5} cm.

"Blue light" as used herein refers to energy waves having a wavelength of at least approximately 4.5×10^{-5} cm but less than 4.9×10^{-5} cm.

"Radiation source" as used herein refers to a source of radiation (as defined above). Examples include, but are not limited to, lamps, the sun, blue lamps, and ultraviolet lamps.

The present invention will be further understood by reference to the following non-limiting examples.

Example 1: *Ex Vivo* Experiments

Ex vivo experiments were performed to obtain quantitative data on polymerization rates and depth of polymerization under skin, fat and muscle.

First, light intensity was measured in the skin. Skin was harvested from a rat and photopolymerization was tested under the epidermis and dermis with no subcutaneous fat, with subcutaneous fat and intramuscular under the skin and fat.

TABLE 1: Experimentally measured light intensity at different levels in the rat skin and the effect of wavelength on the light penetration.

Injection Site (skin thickness)	UVA (% light transmitted)	Blue Light (% light transmitted)
Subcutaneous (~ 1 mm)	4.0%	11.6%
Subcutaneous Fat (~ 1.6 mm)	1.6%	4.8%
Subcutaneous Fat and Muscle (5.0 mm)	0.7%	1.9%

After light intensity was determined, the ability to induce photopolymerization under various thickness skin layers was assessed. Poly(ethylene glycol) (MW 3400, Polysciences, Warrington, PA), end capped with a methacrylate group at both ends (Shearwater Polymers, Huntsville, AL) was polymerized with ultraviolet, blue and visible light as described in U.S. Patent No. 5,567,435 to Hubbel *et al.*, herein incorporated by reference. A differential scanning calorimeter equipped with a

photocalorimeter accessor (Perkin Elmer, Norwalk, CT) was used to photopolymerize under the skin layers and obtain polymerization rates.

Figure 2 predicts the rate of photopolymerization of a polymerizable solution under the subcutaneous, **A**, subcutaneous and fat, **B**, and subcutaneous and fat and muscle, **C**, layers of rat skin. Hence, the polymerization time can be varied from seconds to minutes depending on the wavelength of light, depth of injection, intensity of the incident light, and initiator type and concentration. Even with minimal transmittance of light (*e.g.*, 100 mW/cm² at the skin surface, but approximately 0.6 mW/cm² at the intramuscular layer), polymerization occurs. In essence, polymerization is feasible if the intensity of light reaching the injected polymer solution is at least 0.01 mW/cm². The main influence of light attenuation is the increase in polymerization time and decrease in polymerization rate.

Example 2: *In Vivo* Experiments

Nude mice were injected subcutaneously with a polymerizable solution containing DMA as described in Example 1 and exposed to UVA light from a tanning bed at an intensity of 3-5 mW/cm² for four minutes. The resulting hydrogel was palpated and determined to have polymerized from a liquid to a solid. Controls not exposed to light did not polymerize. In order to further confirm polymerization, the mice were sacrificed and the hydrogel and surrounding skin and tissue were excised. Polymerization was confirmed by swelling the hydrogel in water.

Example 3: Drug Delivery Vehicle

The cogelation of the methacrylated mixed anhydride of succinic acid and poly(ethylene oxide) and dimethacrylate (PEOD) is useful for extending the release of hydrogels. This increases the crosslinking density of PEO networks. A labile anhydride bond in addition to the ester bonds attaching the methacrylate groups of PEO is present in the resulting hydrogels

increasing the mechanisms and rate by which hydrolytic degradation may occur.

This example describes the creation of a photopolymerized succinic acid anhydride/PEO polymer and release of compounds from this polymer.

5 The example is divided as follows: A) mixing succinic acid with polymerizable methacrylate groups, B) mixing release compound with a polymerizable solution of succinic dimethacrylate and PEOD, C) testing swelling, and D) measuring release over time. PEOD was also cogelled with 1,2-(dihydroxyethylene)bisacrylamide and Diallyl-tartardiamide.

10 A. Making Succinic Dimethacrylate (SAD)

Succinic acid was dissolved in anhydrous dimethyl sulfoxide (DMSO, Aldrich, Steinenhofen, Germany) and an excess of methacrylic anhydride (Aldrich, Steinenhofen, Germany) was added. The reaction mixture was purged with argon and heated to 40°C for 24 h. The reaction mixture was
15 cooled to room temperature and precipitated by adding to a 10x excess of ether. The precipitate was vacuum filtered and dried under vacuum.

Infrared spectroscopy was used to monitor substitution of the succinic acid carboxylic acid groups. Comparison of the infrared spectra of succinic acid before and after reaction with methacrylic anhydride shows the
20 disappearance of the wide acid peak centered at 3100cm⁻¹ (*i.e.*, showing the disappearance of the succinic acid carboxylic acid groups).

B. Mixing Release Compound In a Polymerizable Solution

PEOD of MW's 1000 (Polysciences, Warrington, PA) and 3400 (Shearwater Polymers, Huntsville, AL) were utilized as a polymerizable
25 solution. Varying percentages of PEOD and succinic dimethacrylate (SAD) were dissolved in water to form a 50/50% w/v polymerizable solution using approximately 100 mg polymerizable solution. Polymerizable solutions

containing more than 40% succinic dimethacrylate were heated on a hot plate for 2-4 seconds before photopolymerization in order to dissolve the SAD.

5 Bovine serum-albumin (BSA, Sigma, Steizenhofen, Germany) was added to the 50/50% w/v polymerizable solution solutions and vortexed. The polymer solution was subsequently exposed to UV radiation (EFOS Ultracure) in 3 mL PBS and in the presence of HPK (a radical photoactive initiator) for approximately 10 seconds.

10 The gels were incubated at 37°C. At various time points the PBS was removed and frozen while 3 mL fresh PBS was added. Rhodamine was encapsulated in a similar fashion.

C. Measuring Swell Volume

15 The equilibrium swelling volume, Q, correlates to the crosslinking density of a hydrogel. The higher the crosslinking density of a hydrogel, the less volume of water (or other solvent) the network is able to absorb. Gels were swollen in 3 mL phosphate buffered saline (PBS). Swollen weights increased and stabilized after 2 days. The equilibrium swelling volume, Q was calculated using the 2 day swelling weight.

20 Q was calculated for hydrogels ranging from 0 to 70% SAD using PEO of MW 3400 and MW 1000. As predicted, as SAD concentration increases, Q decreases. Hydrogels synthesized from the lower MW PEO (1000) had lower Q values (Figure 3).

D. Measuring Release of Compound

25 The effect of varying SAD hydrogel concentrations on controlled release of albumin was studied. Levels of BSA was quantified using a micro-BSA assay (Pierce) and release was observed by fluorimetry. Figure 4 shows release profiles for hydrogels with 0, 15, 17, 43 and 51% SAD for up to 40 days. All gels exhibited an initial fast release for the first 10 days. The percent of albumin released at the 10 day time point varied with SAD.

The 43 and 51% SAD gels released only 25% of the encapsulated albumin while the 0% SAD gel released 50%. After 10 days the 0% SAD gel released very low levels of albumin while the gels with SAD released on average 1% albumin per day for up to 40 days.

5 Rhodamine (MW 479) was used to study the release of a small molecule for the initial fast release 10 day phase. Hydrogels with 20% SAD released 70-90% of the encapsulated rhodamine during this time period (Figure 5).

10 Thus, cogelation of dimethacrylate succinic acid and poly(ethylene oxide) yields a hydrogel which can slowly release molecules such as rhodamine and albumin. Varying the concentration of succinic acid in the hydrogels is a means to further control the hydrogel swelling and release characteristics.

Example 4: *Ex vivo* and *In vivo* Tissue Engineering

15 In this example, the use of photopolymerizable solutions for tissue engineering was studied *ex vivo* and *in vivo*. For both the *ex vivo* and *in vivo* studies, articular cartilage from the knee, hip and shoulder joints of a pig were dissected for underlying bone, cut into small chips and isolated by incubation with collagenase. Chondrocytes were isolated by differential
20 centrifugation. The isolated chondrocytes were washed and cell number was determined using a hemacytometer.

A. *Ex vivo*

25 While the polymers PEO and PEOD can be used *in vivo* and shows good biocompatibility, the biocompatibility of the initiator was examined *in vitro* using bovine chondrocytes. Although the initiator PHK is approved for dental applications, the initiator was examined without the presence of polymer to ascertain the toxicity of the radical produced to initiate a photopolymerization. The PEOD is very reactive towards the radical so the

lack of polymer would make all radicals available to damage cells (a worst case scenario). Three initiator concentrations (0.1, 0.05 and 0.01 % (w/w)) were examined.

5 Chondrocyte isolated from calf shoulders were maintained ex vivo in cell culture medium (DMEM) at 37°C and 5% CO₂. Cells were passaged approximately once a week. Approximately 10,000 cells per well in an 8-well tissue culture plate were seeded. 1-hydroxycyclohexyl-phenyl-ketone (HPK) was added to DMEM to reach 0.1, 0.05 and 0.01 % (w/w) concentrations. The cells were incubated for 24 hours in the present of the
10 initiator to examine possible acute cell toxicity. The cells were then exposed to UVA radiation (2 mW/cm²) for 3 minutes to activate the photoactive initiator.

To determine the effect of photoactive initiator concentration on cells before exposure to light, cells were exposed to a concentration of 0% (w/w),
15 0.1 % (w/w), 0.05 % (w/w), and 0.01 % (w/w). Little difference is observed between all cases showing that the initiator does not appear to be toxic before exposure to light.

The effect of photoactive initiator concentration on cells after exposure to light for four days was determined by exposing cells to a
20 concentration of 0% (w/w), 0.1 % (w/w), 0.05 % (w/w), and 0.01 % (w/w). The cells were compared morphologically and in relation to cell proliferation for 4 days. After light exposure comparable to that which is needed *in vivo* to cause polymerization (3 minutes at 1-3 mW/cm²), extensive cell death is observed at an initiator concentration of 0.1%. Variable damage is observed
25 at 0.05% and no damage was observed morphologically between the control and the 0.01% cells. Four days after light exposure the 0.01% and control cells had shown similar proliferation.

Further analysis was made between controls which were a) not
30 exposed to initiator or UVA, b) cells exposed to UVA only and c) cells exposed to UVA in the presence of 0.01% PHK. The effect of photoactive

initiator on cells when exposed to no light or photoactive initiator, light only, 0.01% light and initiator, and 24 hours after light exposure was determined. This dose of initiator does not appear to alter proliferation and morphology.

B. *In vivo*

5 The time of degradation of polymer scaffold for tissue engineering is important. While it is not necessary to understand the precise mechanism, it is believed that the proliferating cells need room to multiply and form tissue yet young tissue needs protection from mechanical forces in order to maintain shape. Chondrocytes form neocartilage in only one week when injected
10 alone or with PEG. Therefore it is desirable to have a fast degrading or eroding tissue engineering scaffold.

 While space is needed for the growing tissue, structural support is necessary to maintain construct shape in the presence of the various mechanical forces of surrounding tissue including the skin. The desire for a
15 scaffold with a fast degrading component and one to maintain structural integrity which is injectable led to the use of semi-interpenetrating networks (semi-IPN).

 In this example, the polymer used consisted of 35% PEOD which covalently reacts together to form a porous network in the presence of light.
20 The remaining 65% consisted of PEO MW 100,000 which does not chemically react to form a network, but is trapped within the network formed by PEOD forming a semi-IPN.

 This system provides a twofold degradation. The PEO can diffuse form the network but the covalently connected PEOD must have ester bonds
25 broken before the PEOD chains can be released and excreted. This chemical degradation is slow but may be accelerated by the production of enzymes such as esterases by neocartilage.

 For the *in vivo* studies, the chondrocyte were centrifuged and brought up to a volume to make a concentration of 50×10^6 cells in 900 microliters.

A 35% ratio of methacrylated to nonmethacrylated polymer (Shearwater Sciences, Huntsville, AL) was used. 70 milligrams of PEO (molecular weight 3400, Shearwater Polymers, Huntsville, AL) and 130 milligrams of PEO (molecular weight 100,000 Sigma Chemical, Steinenhofen, Germany) were dissolved in 900 microliters of cells (50×10^6) and media and 100 microliters of 1 mg/ml PHK to form a 20% polymer solution.

Three athymic female mice (Massachusetts General Hospital, Boston, MA) were anesthetized with methoxyflurane and 0.1 milliliter of polymer/chondrocyte solution was injected in four regions subcutaneously using a 22 gauge needle. It was then necessary to show that the cells survived injection and transdermal polymerization. A nude mouse was injected twice with injections similar to those in the cell/polymer implants described below. The mouse was then placed under a lamp emitting UVA radiation. Mice received a light intensity of 1-3 mW/cm² as measured by a radiometer for 3 minutes. The polymer/chondrocyte construct could be palpated to observe polymerization progression.

A mouse was sacrificed at each of one, two and three weeks and the four constructs were removed and fixed in 10% phosphate buffered formalin for 24 hours. Specimens were embedded in paraffined sections. The sections were subsequently stained with hematoxylin and eosin (H&E) and Safranin O according to standard histological technique.

Four constructs per mouse were harvested at 1, 2 and 3 weeks. H&E staining and Safranin O staining of the implants after one week shows that at one week, islands of proliferating chondrocytes are observed. Safranin O stain shows the production of GAG, a product of differentiated chondrocytes. At two weeks, the cells are surrounded by basophilic tissue similar to that of neocartilage. Safranin O staining shows further production in GAG compared to 1 week.

[illegible]

We Claim:

1. A method for forming a tissue equivalent, comprising:
providing a suspension of dissociated cells in a solution of a biocompatible polymer,
wherein the polymer crosslinks upon exposure to free radicals to form a hydrogel,
exposing the suspension to free radicals generated by electromagnetic radiation from
an electromagnetic source external to the suspension so that the electromagnetic radiation
generates free radicals which cause polymer crosslinking and forms the tissue equivalent.
2. The method of Claim 1 wherein the electromagnetic radiation is selected from the
group consisting of x-rays, ultrasound, infrared radiation, far infrared radiation, ultraviolet radiation,
long-wavelength ultraviolet radiation, and visible light.
3. The method of Claim 1 wherein the suspension further comprises a photoinitiator.
4. The method of Claim 3 wherein the photoinitiator is selected from the group
consisting of erythrosin, phloxime, rose bengal, thionine, camphorquinone, ethyl eosin, eosin,
methylene blue, riboflavin, 2,2-dimethyl-2-phenylacetophenone, 2-methoxy-2-phenylacetophenone,
2,2-dimethoxy-2-phenylacetophenone, and other acetophenone derivatives.
5. The method of Claim 4 wherein the suspension further comprises a cocatalyst.
6. The method of Claim 5 wherein the cocatalyst is selected from the group consisting
of N-methyl diethanolamine, N,N-dimethyl benzylamine, triethanolamine, triethylamine,
dibenzylamine, N-benzylethanolamine, and N-isopropyl benzylamine.
7. The method of Claim 6 wherein the cocatalyst is triethanolamine.

SEMI-INTERPENETRATING OR INTERPENETRATING POLYMER NETWORKS FOR DRUG DELIVERY AND TISSUE ENGINEERING

Abstract of the Disclosure

Compositions for tissue engineering and drug delivery have been developed based on solutions of two or more polymers which form semi-interpenetrating or interpenetrating polymer networks upon exposure to active species following injection at a site in a patient in need thereof. The polymers crosslink to themselves but not to each other; semi-interpenetrating networks are formed when only one of the polymers crosslink. The resulting viscous solutions retain the biologically active molecules or cells at the site of injection until release or tissue formation, respectfully, occurs.

As a result of studies conducted with polymer-cell suspensions forming interpenetrating polymer networks, it has been determined that polymer solutions can be formulated wherein the active species is provided by exposure of the polymer solution to an exogenous source of active species, typically electromagnetic radiation, preferably light. Studies demonstrate that light will penetrate through skin, body fluids (such as synovial fluid) and membranes and polymerize the polymer solutions. The polymer solutions can be crosslinked ionically or covalently, to form a hydrogel, semi-interpenetrating polymer network or an interpenetrating polymer network.

FIGURE 1





FIGURE 2



002438-13000
002438-13000

FIGURE 3




FIGURE 4





FIGURE 5



DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below), or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**SEMI-INTERPENETRATING OR INTERPENETRATING POLYMER NETWORKS
FOR DRUG DELIVERY AND TISSUE ENGINEERING**

the specification of which (check one)

_____ is attached hereto

X was filed on May 23, 1997

as application Serial No. 08/862,740

_____ and was amended on: _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)	Priority Claimed
_____ (Number)	_____ (Country)
_____ (Number)	_____ (Country)
_____ (Number)	_____ (Country)

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number	Filing Date
EXPRESS MAIL LABEL NO. <u>EM290166797US</u>	<u>April 11, 1997</u>
Number) _____	(Day/Month/Year Filed)
Number) _____	(Day/Month/Year Filed)
Number) _____	(Day/Month/Year Filed)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	Status
		(patented, pending, abandoned)

(Application Serial No.)	(Filing Date)	Status
		(patented, pending, abandoned)

As named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Patrea L. Pabst	31,284
D. Andrew Floam	34,597
David S. Bradin	37,783
Collen A. Beard	38,824
Robert A. Hodges	P-41,074

Send Correspondence to: Patrea L. Pabst, Esq.
ARNALL GOLDEN & GREGORY LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, GA 30309-3450

Direct telephone calls to: Patrea L. Pabst (404) 873-8794

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Robert S. Langer
Inventor's signature [Signature] Date 7/14/97
Residence 77 Lombard Street, Newton, Massachusetts 02158
Citizenship United States
Post Office Address Same as above

*Semi-Interpenetrating or Interpenetrating Polymer Networks
for Drug Delivery and Tissue Engineering
By: Robert S. Langer, et al.
Filed: May 23, 1997
DECLARATION

Full name of second inventor Jennifer H. Elisseeff

Inventor's signature *[Signature]* Date 7/14/07

Residence 59 Myrtle Street, No. 6, Boston, Massachusetts 02114

Citizenship United States

Post Office Address Same as above[illegible]

*Semi-Interpenetrating or Interpenetrating Polymer Networks
for Drug Delivery and Tissue Engineering
By: Robert S. Langer, et al.
Filed: May 23, 1997
DECLARATION

Full name of third inventor Kristi Anseth


Inventor's signature Kristen Anger

Date 7/21/97

Residence 7464 Singing Hills Drive, Boulder, Colorado 80301

Citizenship United States

Post Office Address Same as above[illegible]

Full name of fourth inventor Derek Sims
Inventor's signature  9/9/97 Date
Residence 224 Kennedy Drive, Malden, Massachusetts 02148
Citizenship United States
Post Office Address Same as above

1. The first part of the report discusses the importance of maintaining accurate records of all transactions, including sales, purchases, and expenses. It emphasizes the need for consistency and transparency in financial reporting.

2. The second part of the report provides a detailed analysis of the company's financial performance over the past year. It includes a comparison of actual results against budgeted figures and identifies areas of strength and weakness.

3. The third part of the report outlines the company's financial strategy for the upcoming year. It includes a discussion of the company's goals, objectives, and the specific actions that will be taken to achieve them.

4. The fourth part of the report provides a summary of the key findings and recommendations. It highlights the areas where the company has made significant progress and identifies the areas that need further attention.

5. The fifth part of the report provides a detailed breakdown of the company's financial data, including a list of all transactions and a summary of the company's financial position.

6. The sixth part of the report provides a detailed breakdown of the company's financial data, including a list of all transactions and a summary of the company's financial position.

7. The seventh part of the report provides a detailed breakdown of the company's financial data, including a list of all transactions and a summary of the company's financial position.

8. The eighth part of the report provides a detailed breakdown of the company's financial data, including a list of all transactions and a summary of the company's financial position.

9. The ninth part of the report provides a detailed breakdown of the company's financial data, including a list of all transactions and a summary of the company's financial position.

10. The tenth part of the report provides a detailed breakdown of the company's financial data, including a list of all transactions and a summary of the company's financial position.